Menu
21/07/2010
HPV Vaccine 'Prolongs Protection' For Genital Warts
Vaccination against certain types of human papillomavirus (HPV) gives strong and sustained protection against genital warts and pre-cancerous growths of the cervix, a new study published on bmj.com has claimed.
The international study found that the quadrivalent HPV vaccine is help in preventing warts ad low grade lesions related to HPV (types 6, 11, 16 and 18).
HPV's are responsible for around 500,000 cases of cervical cancer a year globally and 10 million further cases of high grade cervical intraepithelial neoplasia, which are immediate precusors to malignant cancerous growths.
In addition, it is estimated that 30 million women and men acquire anogenital warts (known as condyloma acuminata) or low-grade cervical growths each year.
The vaccine for HPV types 6, 11, 16 and 18 has the potential to prevent about 70% of cervical cancers and 90% of genital warts, but what contribution the vaccines make to low grade growths is still uncertain.
So, an international group of investigators set out to find how useful the vaccines were in preventing low grade disease.
They studied results from 17,622 women aged 16-26 enrolled into two studies between December 2001 and May 2003. The women were enrolled from primary care centres and university or hospital associated health centres in 24 countries and territories around the world.
The women were split at random into two groups - one group was given three doses of HPV vaccine (for types 6, 11, 16 and 18) at day 1, month 2 and month 6 of the study, while the other women were given a placebo.
Results showed that amongst previously unexposed women who had received the vaccine, it was highly effective (96 - 100%) for preventing low grade lesions attributable to HPV types 6, 11, 16 and 18 for up to four years.
It also had considerable effectiveness against any lesion (regardless of HPV type), with a reduction of 30% of cervical low-grade growths, 48% of vulvar and 75% of vaginal low-grade growths. Genital warts were reduced by 83%.
The report's authors say the prolonged effectivness of the vaccine in preventing low grade lesions is important and conclude: "These lesions occur shortly after infection and a reduction in these lesions will be the earliest clinically noticeable health gain to be realised by HPV vaccination.
"Low-grade cervical and vulvovaginal lesions are important from a public health perspective, as the diagnosis, follow-up and treatment of these common lesions are associated with substantial patient anxiety, morbidity and healthcare costs."
(KMcA/BMcC)
The international study found that the quadrivalent HPV vaccine is help in preventing warts ad low grade lesions related to HPV (types 6, 11, 16 and 18).
HPV's are responsible for around 500,000 cases of cervical cancer a year globally and 10 million further cases of high grade cervical intraepithelial neoplasia, which are immediate precusors to malignant cancerous growths.
In addition, it is estimated that 30 million women and men acquire anogenital warts (known as condyloma acuminata) or low-grade cervical growths each year.
The vaccine for HPV types 6, 11, 16 and 18 has the potential to prevent about 70% of cervical cancers and 90% of genital warts, but what contribution the vaccines make to low grade growths is still uncertain.
So, an international group of investigators set out to find how useful the vaccines were in preventing low grade disease.
They studied results from 17,622 women aged 16-26 enrolled into two studies between December 2001 and May 2003. The women were enrolled from primary care centres and university or hospital associated health centres in 24 countries and territories around the world.
The women were split at random into two groups - one group was given three doses of HPV vaccine (for types 6, 11, 16 and 18) at day 1, month 2 and month 6 of the study, while the other women were given a placebo.
Results showed that amongst previously unexposed women who had received the vaccine, it was highly effective (96 - 100%) for preventing low grade lesions attributable to HPV types 6, 11, 16 and 18 for up to four years.
It also had considerable effectiveness against any lesion (regardless of HPV type), with a reduction of 30% of cervical low-grade growths, 48% of vulvar and 75% of vaginal low-grade growths. Genital warts were reduced by 83%.
The report's authors say the prolonged effectivness of the vaccine in preventing low grade lesions is important and conclude: "These lesions occur shortly after infection and a reduction in these lesions will be the earliest clinically noticeable health gain to be realised by HPV vaccination.
"Low-grade cervical and vulvovaginal lesions are important from a public health perspective, as the diagnosis, follow-up and treatment of these common lesions are associated with substantial patient anxiety, morbidity and healthcare costs."
(KMcA/BMcC)
Related UK National News Stories
Click here for the latest headlines.
17 November 2011
Flu Vaccination Delayed For 'More Advice'
The Department of Health has said on Thursday that it needs further advice from the committee looking into the flu vaccine before it can roll out a larger programme. The announcement follows a request from Health Secretary Andrew Lansley to look at whether the flu vaccination programme should be extended to healthy children.
Flu Vaccination Delayed For 'More Advice'
The Department of Health has said on Thursday that it needs further advice from the committee looking into the flu vaccine before it can roll out a larger programme. The announcement follows a request from Health Secretary Andrew Lansley to look at whether the flu vaccination programme should be extended to healthy children.
17 September 2009
Cervical Cancer Jab 'Lower Among Ethnic Groups'
Strong cultural beliefs and low levels of awareness may curb the uptake of the cervical cancer (HPV) vaccine among certain ethnic groups in the UK, reveals research published ahead of print in the Journal of Epidemiology and Community Health.
Cervical Cancer Jab 'Lower Among Ethnic Groups'
Strong cultural beliefs and low levels of awareness may curb the uptake of the cervical cancer (HPV) vaccine among certain ethnic groups in the UK, reveals research published ahead of print in the Journal of Epidemiology and Community Health.
18 July 2012
Schools Denying Cervical Cancer Vaccine On Religious Grounds
Schoolgirls are being denied a potentially life-saving cervical cancer jab at their schools on religious grounds. The jab guards against two strains of the human papillomavirus (HPV) virus – 16 and 18 – which cause 70% of cases of cervical cancer. It is offered routinely to girls aged 12 to 13.
Schools Denying Cervical Cancer Vaccine On Religious Grounds
Schoolgirls are being denied a potentially life-saving cervical cancer jab at their schools on religious grounds. The jab guards against two strains of the human papillomavirus (HPV) virus – 16 and 18 – which cause 70% of cases of cervical cancer. It is offered routinely to girls aged 12 to 13.
09 July 2010
Skin Cancer Linked To Warts Infection
Suffering the virus that causes warts and verrucas can increase the risk of certain cancers. An international team of researchers has found that people with several types of the virus - human papillomaviruses (HPVs) - were more than one and a half times as likely to develop certain skin cancers compared to people with no HPVs.
Skin Cancer Linked To Warts Infection
Suffering the virus that causes warts and verrucas can increase the risk of certain cancers. An international team of researchers has found that people with several types of the virus - human papillomaviruses (HPVs) - were more than one and a half times as likely to develop certain skin cancers compared to people with no HPVs.
04 February 2014
Cervical Cancer Vaccine Could Be 'Hugely Beneficial' To Boys
A vaccination that protects girls from cervical cancer could be used to save thousands of boys lives in Britain. The jab, which immunises 12 and 13-year-old girls against Human Papilloma Virus (HPV), would be "hugely beneficial" to boys as well, according to campaigners.
Cervical Cancer Vaccine Could Be 'Hugely Beneficial' To Boys
A vaccination that protects girls from cervical cancer could be used to save thousands of boys lives in Britain. The jab, which immunises 12 and 13-year-old girls against Human Papilloma Virus (HPV), would be "hugely beneficial" to boys as well, according to campaigners.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
